Development and validation of a model to predict the outcomes of radical cystectomy in patients with bladder cancer
Wataru Fukuokaya(Jikei University School of Medicine), Takahiro Kimura(Jikei University School of Medicine), Tomokazu Sazuka(Chiba University), Fumihiko Urabe(Jikei University School of Medicine), Hiroshi Kitamura(Tohoku University), Yoshiyuki Matsui(Tokyo National Hospital), Jun Miki(Jikei University School of Medicine), Takeshi Sano(Tokushima University), Rikiya Taoka(Kagawa University), Soki Kashima(Akita University), Yoji Murakami(Kumamoto University), Ryoichi Saito(University of Miyazaki), Hirohito Naito(Kagawa University), Hiroyuki Nishiyama(University of Tsukuba), Ayumu Matsuda(Tokyo National Hospital), Minoru Katō(Osaka Metropolitan University), Takashi Kawahara(University of Tsukuba), Naotaka Nishiyama(University of Toyama), Shingo Hatakeyama(Hirosaki University), Taketo Kawai(National Center for Global Health and Medicine)
Cited by 1
Related Papers
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
|Nature|2021|603
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
|The Lancet Oncology|2021|532
Extracellular vesicles as biomarkers and therapeutic targets for cancer
|American Journal of Physiology-Cell Physiology|2019|412
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial
|The Lancet Oncology|2021|411
A Glycine-rich RNA-binding Protein Mediating Cold-inducible Suppression of Mammalian Cell Growth
|The Journal of Cell Biology|1997|388